$178.78
+0.047%Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
Chairman of Scientific Advisory Board & Chief Science Officer
Compensation
$139,555
Chief Executive Officer & Director
Chief Financial Officer
Compensation
$1,473,831
Chief Human Resources Officer
Chief Marketing & Strategy Officer
Chief Operating Officer
Compensation
$1,535,895
Chief Operating Officer of Consumer Division
Compensation
$881,703
Chief Technology & Innovation Officer
Executive Vice President & Chief Financial Officer
Compensation
$1,473,831
Executive Vice President & Chief Information Officer
Compensation
$1,100,540
Executive Vice President of Operations
Compensation
$774,840
Executive Vice President of Operations & Clinical Research
Compensation
$774,840
During the last 12 months, insiders have purchased $468K and sold $1.63M worth of MASI shares, resulting in $1.16M of net selling activity.
0
0.00
0
0.00
+0
+$0
0
0.00
11.9K
1.63M
-1.6M
-$1.63M
0
0.00
0
0.00
+0
+$0
3.2K
468.50K
0
0.00
+468K
+$468K
Jellison William R
Director
$438K
Brennan Michelle
Director, Other: Chairman Of The Board
$31K
Sampath Anand
Officer: Evp, Ops & Clinical Research
$1.63M
Strong bearish signal with $1.16M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Weak buy/sell ratio. Selling significantly exceeds buyingโmonitor for potential fundamental concerns.
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
MASI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | March 26, 2025 | April 29, 2025 | 2025 | |
DEF 14A DEF 14A 2022 N/A | April 05, 2022 | January 01, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 15, 2021 | January 02, 2021 | 2021 | |
DEF 14A DEF 14A 2019 N/A | April 16, 2020 | December 28, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 12, 2019 | December 29, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 20, 2018 | December 30, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | April 12, 2017 | December 31, 2016 | 2016 | |
DEF 14A DEF 14A 2016 N/A | March 16, 2016 | January 02, 2016 | 2016 | |
DEF 14A DEF 14A 2015 N/A | May 04, 2015 | January 03, 2015 | 2015 | |
DEF 14A DEF 14A 2014 N/A | April 28, 2014 | June 05, 2014 | 2014 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.